Jean-Jacques Kiladjian/LinkedIn
Dec 8, 2025, 14:46
Jean Jacques Kiladjian Presents 1st Results of the ROP-ET Study at ASH25
Jean Jacques Kiladjian, Head of Clinical Research Department of Inserm, shared on LinkedIn:
”Proud to have presented at American Society of Hematology ASH25 , on behalf of my co-investigators from 10 European countries, the first results of the ROP-ET study showing that ropeginterferon-alpha 2b is also an effective and safe treatment for patients with essential thrombocythemia ET who have no other therapeutic option.
At 12 months: 65% of durable (>3 months) complete hematologic response, no disease progression, only 1.5% of major thrombotic events, symptoms improvement in 62% of patients.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 11:55Akinchan Bhardwaj: Exercise Biological Modifier of Vascular Trajectory
-
Mar 12, 2026, 11:50Guy Young: Clinical Conversations on Gene Therapy Progress in Hemophilia B at THSNA 2026
-
Mar 12, 2026, 11:44Yves Bikorimana: Causes, Diagnosis, and Management of Neonatal Alloimmune Thrombocytopenia
-
Mar 12, 2026, 11:33Kymentie Ferdinande: New Insights Into Platelet Function and Thrombus Formation in Cirrhosis
-
Mar 12, 2026, 11:17Tareq Abadl: Why Do Some People Bruise And Bleed So Easily?
-
Mar 12, 2026, 11:15Matthew Flick: The Interplay of the Fibrinogen αC-Region, Hypofibrinogenemia, and GPVI in Arterial Thrombosis
-
Mar 12, 2026, 11:08Stephen Twumasi: The Impact of Hepatitis B Infection on the Coagulation System During Pregnancy
-
Mar 12, 2026, 11:05Robert Lufkin: One Minute of Wisdom from Robert Lustig on Cholesterol, Sugar, and Heart Disease
-
Mar 12, 2026, 10:36Cynthia Dunbar: Retiring From NIH After 39 Years to Advance Advocacy and Research in Hematology